Knight Therapeutics Reports Q4 and Year Ended December 31, 2024 Financial Results
Montreal, March 20, 2025 – Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2024. All currency amounts are in thousands, except for share and per share amounts.
Fourth Quarter Financial Highlights
Revenue for the fourth quarter was $149,285, an increase of 13% compared to the same quarter last year. Adjusted EBITDA was $18,629, compared to $19,465 in the fourth quarter of 2023. Net loss for the quarter was $5,887, compared to a net loss of $2,286 in the same period last year.
Full Year Financial Highlights
Revenue for the year ended December 31, 2024, was $532,057, an increase of 18% compared to the previous year. Adjusted EBITDA was $51,349, compared to $57,227 in the previous year. Net loss for the year was $18,135, compared to a net loss of $13,273 in the previous year.
Business Updates
During the year, Knight launched three new products: Alproliq, a treatment for osteoporosis, Omontys, a treatment for anemia, and Sensipar, a treatment for secondary hyperparathyroidism. The Company also expanded its commercial footprint in Latin America, establishing a subsidiary in Colombia and launching its first product in the country.
Impact on Individuals
The financial results and business updates from Knight Therapeutics may not have a direct impact on individuals, as they primarily relate to the Company’s financial performance and business operations. However, the launch of new treatments for conditions such as osteoporosis, anemia, and secondary hyperparathyroidism may provide relief and improved health outcomes for patients suffering from these conditions.
Impact on the World
The specialty pharmaceutical industry plays a significant role in the global healthcare system, and the financial results and business updates from Knight Therapeutics may have indirect impacts on the world. The launch of new treatments for conditions such as osteoporosis, anemia, and secondary hyperparathyroidism may improve the quality of life for patients and reduce healthcare costs associated with managing these conditions. Additionally, Knight’s expansion into new markets, such as Colombia, may contribute to increased access to healthcare and improved health outcomes in those regions.
Conclusion
In conclusion, Knight Therapeutics reported solid financial results for the fourth quarter and year ended December 31, 2024, despite a net loss for the year. The Company launched three new products and expanded its commercial footprint in Latin America. While the financial results and business updates may not have a direct impact on individuals, the launch of new treatments for conditions such as osteoporosis, anemia, and secondary hyperparathyroidism may provide relief and improved health outcomes for patients. Additionally, Knight’s expansion into new markets may contribute to increased access to healthcare and improved health outcomes in those regions.
- Knight Therapeutics reported solid financial results for Q4 and year ended December 31, 2024.
- The Company launched three new products: Alproliq, Omontys, and Sensipar.
- Knight expanded its commercial footprint in Latin America, establishing a subsidiary in Colombia and launching its first product in the country.
- The launch of new treatments for conditions such as osteoporosis, anemia, and secondary hyperparathyroidism may provide relief and improved health outcomes for patients.
- Knight’s expansion into new markets may contribute to increased access to healthcare and improved health outcomes in those regions.
